Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2359 - Phase II study: Letrozole maintenance therapy after first line chemotherapy in patients with advanced serous and endometrioid ovarian cancer


29 Sep 2019


Poster Display session 2


Tumour Site

Ovarian Cancer


Alexandra Tyulyandina


Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


A. Tyulyandina1, A. Rumyantsev1, I. Pokataev1, V. Nechushkina2, K. Morkhov2, Y. Sergeev3, V. Mochalnikova4, A. Bulanov1, M. Stenina1, S. Tjulandin1

Author affiliations

  • 1 Chemotherapy And Clinical Pharmacology Department, N. N. Blokhin Russian Cancer Research Center, 117535 - Moscow/RU
  • 2 Gynecologic Oncology Department, N. N. Blokhin Russian Cancer Research Center, 117535 - Moscow/RU
  • 3 Radiologic Surgery Department, N. N. Blokhin Russian Cancer Research Center, 117535 - Moscow/RU
  • 4 Pathology Department, N. N. Blokhin Russian Cancer Research Center, 117535 - Moscow/RU


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2359


The role of hormonal therapy in the treatment of advanced ovarian cancer (OC) has not been determined yet. Recently the hormone maintenance therapy (HMT) has been actively discussed.


70 patients (pts) with serous and endometrioid OC stage Ic-IV after 1st line chemotherapy (CT) with paclitaxel/platinum agents and complete (CR) or partial response (PR) were enrolled in phase II study. Pts received HMT with letrozole 2,5 mg per day for 5 years or until disease progression. 71 pts with the same criteria who observed after 1st line CT was taken as retrospective control group. The groups were comparable at baseline including BRCA1/2 status. Paraffin-embedded material (N = 141) after cytoreductive surgery was assessed for presence of estrogen/progesterone receptors (ER/PR) (IGH) and Ki67 in both groups.


Median progression-free survival (PFS) and overall survival (OS) after letrozole maintenance were 18.7 and 51.2 months respectively. In retrospective analysis PFS was significantly longer in letrozole group than in observational group (18.7 and 16.9 months, p = 0.05; HR 0.68, 95%CI 0.44-0.98). There was no any significant difference in overall survival in HMT and observational groups. In the observational group 26 (36,6%) pts received hormone therapy for disease progression later. The expression of ER, PR and Ki67 didn’t have any prognostic and predictive role. Multivariate Cox regression analysis for PFS showed that administration of HMT, stage and response after CT associated with significantly longer PFS. Based on subgroup analysis only pts with stage III-IV with CR after 1st line had significantly longer PFS than pts who underwent observation: 20.9 vs 17.7 months (p = 0.05; HR 0.56, 95%CI 0.32-0.99).


HMT with letrozole could be effective in pts with advanced serous and endometriod OC stage III-IV with CR after 1st line CT regardless of tumour grade. Further randomized studies of HMT are needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.